Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
1.
BMC Pediatr ; 24(1): 532, 2024 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-39164659

RESUMEN

BACKGROUND: Alagille syndrome (ALGS) is a multisystem genetic disorder frequently characterized by hepatic manifestations. This study analyzed the clinical, pathological, and molecular genetic features of ALGS to improve the efficiency of clinical diagnosis. METHODS: We retrospectively analyzed the clinical manifestations, pathological examination findings, and genetic testing results of 17 children diagnosed with ALGS based on the revised criteria and hospitalized at our center from January 2012 to January 2022. RESULTS: The clinical manifestations are as follows: Cholestasis (16/17, 94%), characteristic facies (15/17, 88%), heart disease (12/16, 75%), butterfly vertebrae (12/17, 71%) and posterior embryotoxon (7/12, 58%). Among the 15 patients who underwent liver pathology examination, 13 (87%) were found to have varying degrees of bile duct paucity. Genetic testing was performed on 15 children, and pathogenic variants of the jagged canonical Notch ligand 1 (JAG1) gene were identified in 13 individuals, including 4 novel variants. No pathogenic variant in the notch homolog 2 (NOTCH2) gene were identified, and 2 children exhibited none of the aforementioned gene pathogenic variants. The median follow-up duration was 7 years. Of the remaining 15 patients (excluding 2 lost to follow-up), 11 remained stable, 4 deteriorated, and no patient died during the follow-up period. CONCLUSIONS: Among children diagnosed with ALGS, cholestasis stands as the most common feature. To minimize the risk of misdiagnosis, genetic testing should be performed on children exhibiting cholestasis, followed by the application of the revised diagnostic criteria for ALGS. While pharmacological therapy has shown effectiveness for ALGS patients, liver transplantation may be considered in instances of severe pruritus.


Asunto(s)
Síndrome de Alagille , Pruebas Genéticas , Proteína Jagged-1 , Humanos , Síndrome de Alagille/genética , Síndrome de Alagille/diagnóstico , Masculino , Femenino , Estudios Retrospectivos , Preescolar , Lactante , Proteína Jagged-1/genética , Niño , Colestasis/genética
3.
Andes Pediatr ; 95(2): 196-201, 2024 Apr.
Artículo en Español | MEDLINE | ID: mdl-38801368

RESUMEN

Alagille syndrome (ALGS) is an autosomal dominant, multisystem disorder that typically presents with cholestasis, cardiac, ocular, skeletal, vascular and renal abnormalities, and distinct facial features. Most cases are due to variants in the JAG1 gene, with only a small percentage involving a complete gene deletion. OBJECTIVE: to contribute to the phenotype delineation and interpretation of a microdeletion not previously described in the literature on chromosome 20. CLINICAL CASE: A 4-month-old female patient was diagnosed with a heart murmur. An echocardiogram revealed pulmonary artery stenosis, which, combined with a prominent forehead observed on physical examination, determined her referral to clinical genetics. Because ALGS was suspected, complementary studies were performed, revealing butterfly vertebras and a genetic panel identified a pathogenic heterozygous deletion, encompassing the entire coding sequence of the JAG1 gene. To rule out a more extensive deletion, a chromosome microarray was performed, confirming a pathogenic microdeletion on chromosome 20 of 378 kb (arr[GRCh37] 20p12.2(10414643_10792802)x1). CONCLUSIONS: A targeted sequencing panel followed by confirmation with a chromosome microarray allowed the identification and delineation of a pathogenic microdeletion not previously reported in the literature, including the complete JAG1 gene in a Chilean patient whose phenotype is consistent with ALGS.


Asunto(s)
Síndrome de Alagille , Eliminación de Gen , Proteína Jagged-1 , Humanos , Síndrome de Alagille/genética , Síndrome de Alagille/diagnóstico , Proteína Jagged-1/genética , Femenino , Lactante , Fenotipo
4.
Exp Clin Transplant ; 22(2): 160-164, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38511987

RESUMEN

Alagille syndrome is an autosomal-dominantinherited disease characterized by intrahepatic bile duct involvement, congenital heart disease, eye anomalies, skeletal and central nervous system involvement, kidney anomalies, and facial appearance. Liver transplant is the only treatment option for patients with end-stage liver disease and Alagille syndrome. Bilateral peripheral pulmonary artery stenosis is a contraindication for liver transplant due to high mortality, and the decision for liver transplant in patients with bilateral peripheral pulmonary artery stenosis is extremely challenging for anesthesiologists andtransplant surgeons.Wepresent a 2-year-oldfemale patient with successful anesthetic management of a pediatric living donor liver transplant with mild bilateral pulmonary artery stenosis, mild aortic stenosis, and mitral regurgitation due to Alagille syndrome. Anesthesiologists should know the underlying pathophysiological condition and perform a comprehensive preoperative evaluation to determine the correct anesthesia plan in patients with Alagille syndrome who will undergo liver transplants to treat multiple system disorders. Successful perioperative management of Alagille syndrome requires effective communication and collaboration between specialists through a multidisciplinary team approach.


Asunto(s)
Síndrome de Alagille , Anestesia , Trasplante de Hígado , Estenosis de Arteria Pulmonar , Humanos , Niño , Preescolar , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/cirugía , Trasplante de Hígado/efectos adversos , Donadores Vivos , Arteria Pulmonar
5.
Ophthalmic Genet ; 45(3): 299-302, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38526149

RESUMEN

INTRODUCTION: Alagille syndrome (AGS) is a genetic disease with multisystemic affection, including ocular manifestations. Recently, a high frequency of posterior segment findings, including macular changes, has been reported. This publication aims to report an unusual finding of macular atrophy and a focal choroidal excavation in a patient with JAG1 related AGS. METHODS: Case report. RESULTS: This publication describes an atypical presentation of focal choroidal excavation (FCE) and unilateral macular atrophy in a 7-year-old male with Alagille syndrome (AGS). Genetic analysis revealed a pathogenic variant in the JAG1 gene. Ophthalmological examination and imaging findings demonstrated characteristic ocular manifestations of AGS, including posterior embryotoxon, chorioretinal atrophy, and thinning of the choroid. CONCLUSION: The presence of FCE in AGS is uncommon, and the underlying mechanisms remain unclear. Further exploration of similar cases is necessary to better understand the evolution and visual prognosis in patients with AGS and FCE.


This case report highlights the presence of focal choroidal excavation and unilateral macular atrophy in a patient with Alagille syndrome. The genetic analysis identified a pathogenic variant in the JAG1 gene.


Asunto(s)
Síndrome de Alagille , Proteína Jagged-1 , Humanos , Síndrome de Alagille/genética , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/patología , Proteína Jagged-1/genética , Masculino , Niño , Tomografía de Coherencia Óptica , Enfermedades de la Coroides/genética , Enfermedades de la Coroides/diagnóstico , Angiografía con Fluoresceína , Agudeza Visual/fisiología , Atrofia , Mácula Lútea/patología , Mácula Lútea/anomalías , Coroides/patología , Coroides/anomalías
6.
J Gastroenterol Hepatol ; 39(5): 964-974, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38323732

RESUMEN

BACKGROUND AND AIM: Advances in molecular genetics have uncovered causative genes responsible for neonatal cholestasis. Panel-based next-generation sequencing has been used clinically in infants with neonatal cholestasis. We aimed to evaluate the clinical application of single-gene testing and next-generation sequencing and to develop a diagnostic algorithm for neonatal intrahepatic cholestasis. METHODS: From January 2010 to July 2021, patients suspected of having neonatal intrahepatic cholestasis were tested at the Seoul National University Hospital. If there was a clinically suspected disease, single-gene testing was performed. Alternatively, if it was clinically difficult to differentiate, a neonatal cholestasis gene panel test containing 34 genes was performed. RESULTS: Of the total 148 patients examined, 49 (33.1%) were received a confirmed genetic diagnosis, including 14 with Alagille syndrome, 14 with neonatal intrahepatic cholestasis caused by citrin deficiency, 7 with Dubin-Johnson syndrome, 5 with arthrogryposis-renal dysfunction-cholestasis syndrome, 5 with progressive familial intrahepatic cholestasis type II, 1 with Rotor syndrome, 1 with Niemann-Pick disease type C, 1 with Kabuki syndrome, and 1 with Phenylalanyl-tRNA synthetase subunit alpha mutation. Sixteen novel pathogenic or likely pathogenic variants of neonatal cholestasis were observed in this study. Based on the clinical characteristics and laboratory findings, we developed a diagnostic algorithm for neonatal intrahepatic cholestasis by integrating single-gene testing and next-generation sequencing. CONCLUSIONS: Alagille syndrome and neonatal intrahepatic cholestasis caused by citrin deficiency were the most common diseases associated with genetic neonatal cholestasis. Single-gene testing and next-generation sequencing are important and complementary tools for the diagnosis of genetic neonatal cholestasis.


Asunto(s)
Algoritmos , Colestasis Intrahepática , Pruebas Genéticas , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Colestasis Intrahepática/genética , Colestasis Intrahepática/diagnóstico , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Recién Nacido , Pruebas Genéticas/métodos , Masculino , Femenino , Síndrome de Alagille/genética , Síndrome de Alagille/diagnóstico , Lactante
7.
BMJ Case Rep ; 17(2)2024 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-38417945

RESUMEN

Alagille syndrome (AGS) is a genetic disorder due to mutations in the JAGGED 1 or NOTCH 2 genes leading to multisystemic manifestations. Though these patients are at risk of developing various liver tumours, no cases of hepatoblastoma among young children with cirrhosis in AGS have been reported. We report a male toddler, with cirrhosis due to AGS who developed a hepatoblastoma. He underwent a liver transplant for decompensated chronic liver disease with marked pruritus, very high alpha-fetoprotein levels and malignant liver lesions on positron emission tomography CT. His explant histology revealed a paucity of bile ducts and liver lesions turned out to be hepatoblastoma for which he received postoperative chemotherapy. The genetic testing sent before transplantation confirmed the clinical diagnosis of AGS. Hepatoblastoma should be suspected in any child with AGS presenting with a right upper quadrant mass even in the setting of chronic liver disease.


Asunto(s)
Síndrome de Alagille , Hepatoblastoma , Neoplasias Hepáticas , Humanos , Masculino , Lactante , Preescolar , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/genética , Hepatoblastoma/complicaciones , Hepatoblastoma/diagnóstico , Hepatoblastoma/genética , Tomografía Computarizada por Rayos X , Neoplasias Hepáticas/complicaciones , Cirrosis Hepática/complicaciones
8.
Curr Opin Cell Biol ; 86: 102302, 2024 02.
Artículo en Inglés | MEDLINE | ID: mdl-38194749

RESUMEN

Notch signaling controls multiple aspects of embryonic development and adult homeostasis. Alagille syndrome is usually caused by a single mutation in the jagged canonical Notch ligand 1 (JAG1), and manifests with liver disease and cardiovascular symptoms that are a direct consequence of JAG1 haploinsufficiency. Recent insights into Jag1/Notch-controlled developmental and homeostatic processes explain how pathology develops in the hepatic and cardiovascular systems and, together with recent elucidation of mechanisms modulating liver regeneration, provide a basis for therapeutic efforts. Importantly, disease presentation can be regulated by genetic modifiers, that may also be therapeutically leverageable. Here, we summarize recent insights into how Jag1 controls processes of relevance to Alagille syndrome, focused on Jag1/Notch functions in hepatic and cardiovascular development and homeostasis.


Asunto(s)
Síndrome de Alagille , Humanos , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/genética , Síndrome de Alagille/terapia , Proteínas Serrate-Jagged , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Proteínas de Unión al Calcio/genética , Péptidos y Proteínas de Señalización Intercelular/genética , Proteína Jagged-1/genética
9.
Hepatol Commun ; 8(1)2024 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-38180987

RESUMEN

BACKGROUND: Mitochondrial hepatopathies (MHs) are primary mitochondrial genetic disorders that can present as childhood liver disease. No recognized biomarkers discriminate MH from other childhood liver diseases. The protein biomarkers growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) differentiate mitochondrial myopathies from other myopathies. We evaluated these biomarkers to determine if they discriminate MH from other liver diseases in children. METHODS: Serum biomarkers were measured in 36 children with MH (17 had a genetic diagnosis); 38 each with biliary atresia, α1-antitrypsin deficiency, and Alagille syndrome; 20 with NASH; and 186 controls. RESULTS: GDF15 levels compared to controls were mildly elevated in patients with α1-antitrypsin deficiency, Alagille syndrome, and biliary atresia-young subgroup, but markedly elevated in MH (p<0.001). FGF21 levels were mildly elevated in NASH and markedly elevated in MH (p<0.001). Both biomarkers were higher in patients with MH with a known genetic cause but were similar in acute and chronic presentations. Both markers had a strong performance to identify MH with a molecular diagnosis with the AUC for GDF15 0.93±0.04 and for FGF21 0.90±0.06. Simultaneous elevation of both markers >98th percentile of controls identified genetically confirmed MH with a sensitivity of 88% and specificity of 96%. In MH, independent predictors of survival without requiring liver transplantation were international normalized ratio and either GDF15 or FGF21 levels, with levels <2000 ng/L predicting survival without liver transplantation (p<0.01). CONCLUSIONS: GDF15 and FGF21 are significantly higher in children with MH compared to other childhood liver diseases and controls and, when combined, were predictive of MH and had prognostic implications.


Asunto(s)
Síndrome de Alagille , Atresia Biliar , Factor 15 de Diferenciación de Crecimiento , Enfermedad del Hígado Graso no Alcohólico , Niño , Humanos , Síndrome de Alagille/diagnóstico , Atresia Biliar/diagnóstico , Biomarcadores , Factor 15 de Diferenciación de Crecimiento/sangre , Factor 15 de Diferenciación de Crecimiento/química , Enfermedades Mitocondriales/diagnóstico
10.
Sci Rep ; 14(1): 1812, 2024 01 20.
Artículo en Inglés | MEDLINE | ID: mdl-38245625

RESUMEN

Alagille Syndrome (ALGS) is a complex genetic disorder characterized by cholestasis, congenital cardiac anomalies, and butterfly vertebrae. The variable phenotypic expression of ALGS can lead to challenges in accurately diagnosing affected infants, potentially resulting in misdiagnoses or underdiagnoses. This study highlights novel JAG1 gene mutations in two cases of ALGS. The first case with a novel p.Pro325Leufs*87 variant was diagnosed at 2 months of age and exhibited a favorable prognosis and an unexpected manifestation of congenital hypothyroidism. Before the age of 2, the second patient was incorrectly diagnosed with liver structural abnormalities, necessitating extensive treatment. In addition, he exhibited delays in language acquisition that may have been a result of SNAP25 haploinsufficiency. The identification of ALGS remains challenging, highlighting the importance of early detection and genetic testing for effective patient management. The variant p.Pro325Leufs*87 is distinct from reported variants linked to congenital hypothyroidism in ALGS patients, thereby further confirming the clinical and genetic complexity of ALGS. This emphasizes the critical need for individualized and innovative approaches to diagnosis and medical interventions, uniquely intended to address the complexity of this syndrome.


Asunto(s)
Síndrome de Alagille , Hipotiroidismo Congénito , Humanos , Lactante , Masculino , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/genética , China , Hipotiroidismo Congénito/genética , Pruebas Genéticas , Proteína Jagged-1/genética
11.
Arch. pediatr. Urug ; 94(1): e302, 2023. ilus
Artículo en Español | LILACS, UY-BNMED, BNUY | ID: biblio-1420114

RESUMEN

El síndrome de Alagille es una patología poco frecuente, de herencia autosómica dominante. Se caracteriza por la presencia de colestasis crónica progresiva ocasionada por hipoplasia de las vías biliares; anomalías vertebrales, oculares y cardíacas, y fenotipo facial particular. Entre sus diagnósticos diferenciales se incluyen las infecciones, enfermedades endocrinometabólicas, atresia biliar y causas idiopáticas. El pronóstico de este síndrome es variable y depende de la entidad de la afectación hepática y los defectos cardiovasculares. El abordaje terapéutico suele ser interdisciplinario e individualizado, enfocado en el control sintomático, prevención de la malnutrición y el déficit de vitaminas liposolubles. Se presenta el caso de un lactante de 2 meses en el que se estudiaron las causas más frecuentes de colestasis y se llegó al diagnóstico de síndrome de Alagille. Se describe su abordaje terapéutico y seguimiento.


Alagille syndrome is an inherited autosomal dominant rare disease. It is characterized by the presence of progressive chronic cholestasis caused by hypoplasia of the bile ducts; vertebral, ocular and cardiac anomalies, and particular facial phenotype. Its differential diagnoses include infections, endocrine-metabolic diseases, biliary atresia and idiopathic causes. The prognosis of this syndrome is variable and depends on the degree of liver involvement and cardiovascular defects. The therapeutic approach is usually interdisciplinary and customized, focused on symptomatic control, prevention of malnutrition and fat-soluble vitamin deficiency. We present the case of a 2-month-old infant in whom the most frequent causes of cholestasis were studied and to whom Alagille Syndrome was diagnosed. We hereby describe its therapeutic approach and follow-up.


A síndrome de Alagille é uma doença rara, hereditária, autossômica e dominante. Caracteriza-se pela presença de colestase crônica progressiva causada por hipoplasia das vias biliares; anomalias vertebrais, oculares e cardíacas e fenótipo facial particular. Seus diagnósticos diferenciais incluem infecções, doenças endócrino-metabólicas, atresia biliar e causas idiopáticas. O prognóstico desta síndrome é variável e depende do grau de envolvimento hepático e defeitos cardiovasculares. A abordagem terapêutica geralmente é interdisciplinar e personalizada, focada no controle sintomático, prevenção da desnutrição e deficiência de vitaminas lipossolúveis. Apresentamos o caso de uma criança de 2 meses de idade em que foram estudadas as causas mais frequentes de colestase e a quem foi diagnosticada Síndrome de Alagille. Descrevemos a sua abordagem terapêutica e seguimento.


Asunto(s)
Humanos , Femenino , Lactante , Colestasis/diagnóstico , Síndrome de Alagille/diagnóstico , Ácido Ursodesoxicólico/uso terapéutico , Vitaminas Liposolubles , Colestasis/etiología , Colestasis/tratamiento farmacológico , Síndrome de Alagille/complicaciones , Síndrome de Alagille/terapia , Diagnóstico Diferencial
12.
Rev. pediatr. electrón ; 16(1): 18-24, abr. 2019. ilus, tab
Artículo en Español | LILACS | ID: biblio-998476

RESUMEN

Resumen Introducción: El síndrome de Alagille es una enfermedad con múltiples afectaciones, es autosómica dominante, con expresividad variable. Se identifica por manifestaciones hepáticas, vertebrales, cardiacas, oculares y dismorfia facial. Objetivo: Reportar un caso de S. de Alagille con afectación hepática, que debuta con hemorragia de vías digestivas altas. Materiales y métodos: Reporte de caso clínico confrontando con artículos de revisiones de temas en búsqueda electrónica en bases de datos de RIMA, MEDLINE, PUBMED, MEDSCAPE, de 1993-2018. Resultado: Paciente de 2 años, con diagnóstico tardío de enfermedad hepática, con progresión a cirrosis y hallazgos al examen físico que confirman Síndrome de Alagille. Se confirma el diagnóstico molecular coincidiendo con el principal hallazgo genético con anomalías asociadas al gen Jagged 1 (JAG1) localizado en el cromosoma 20 y el NOTCH2 del cromosoma 1. Conclusiones: Es de gran importancia resaltar esta patología infrecuente la cual representa un reto diagnóstico, debe tenerse en cuenta la múltiple afectación orgánica por lo cual es fundamental un manejo interdisciplinario


Abstract Introduction: Alagille syndrome is a disease with multiple impairments, is autosomal dominant with variable expressivity. It is identified by manifestations of vertebral, liver, heart, eye and facial dysmorphia. Objective: Report a case of Alagille S. with hepatic involvement, debuting with hemorrhage of upper digestive tract. Materials and methods: Clinical case report confronting articles reviewing subjects in electronic search in RIMA databases, MEDLINE, PUBMED, MEDSCAPE, from 1993-2018. Result: 2 year old patient, with late diagnosis of liver disease, with progression to cirrhosis and physical exam findings that confirm Alagille Syndrome. Confirmed the diagnostic molecular coinciding with the main genetic finding which are anomalies associated with the gene Jagged 1 (JAG1) located on chromosome 20 and the NOTCH2 of chromosome 1. Conclusions: It is important to highlight this uncommon disease which poses a diagnostic challenge, multiple organic involvement must be taken into account by which an interdisciplinary management is essential.


Asunto(s)
Humanos , Masculino , Preescolar , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Hemorragia Gastrointestinal/etiología , Colestasis/diagnóstico , Colestasis/etiología , Síndrome de Alagille/genética , Síndrome de Alagille/terapia , Receptor Notch2 , Cara/anomalías , Proteína Jagged-1 , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/etiología
13.
s.l; s.n; 2016.
No convencional en Español | LILACS, BRISA | ID: biblio-833429

RESUMEN

La indicación solicitada para evaluación de la tecnología "Examen genético para la detección de las mutaciones y deleciones del GEN JAGGED1 (JAG1)" corresponde a la indicación diagnóstica referida en la literatura médica. Se acepta la cobertura a la tecnología para confirmación molecular para síndrome de Alagille, estando sujeta obligatoriamente a los procesos de control con los que el Seguro Integral de Salud cuenta o cree.(AU)


Asunto(s)
Pruebas Genéticas , Síndrome de Alagille/diagnóstico , Financiación de la Atención de la Salud , Directrices para la Planificación en Salud , Mutación , Evaluación de la Tecnología Biomédica
14.
Pediatr. (Asunción) ; 41(1): 51-56, abr. 2014.
Artículo en Español | LILACS, BDNPAR | ID: lil-711874

RESUMEN

El Síndrome de Allagile, conocido también como síndrome de Alagille-Watson y displasia arterio hepática se caracteriza por una colestasis crónica producida por una hipoplasia de las vías biliares intrahepáticas. Se asocia a malformaciones congénitas cardiacas, renales y esqueléticas en pacientes con un fenotipo peculiar. Estas características constituyen los cinco criterios clásicos de diagnóstico. La biopsia hepática ya no es imprescindible para el diagnóstico, siempre y cuando exista ictericia colestasica. El tratamiento es sintomático. El trasplante hepático debe plantearse solo en caso de falla hepática porque la sobrevida no es buena. Se presenta el caso de una niña con diagnóstico de Síndrome de Allagile, que presentó cuatro de los cinco criterios clásicos.


Asunto(s)
Niño , Síndrome de Alagille , Síndrome de Alagille/diagnóstico
15.
Arch. argent. pediatr ; 110(6): 509-515, dic. 2012. ilus, tab
Artículo en Español | LILACS | ID: lil-662132

RESUMEN

El síndrome de Alagille (SA) es una enfermedad autosómica dominante multisistémica, con expresión variable. Las principales manifestaciones son: colestasis crónica, enfermedad cardíaca congénita, embriotoxón posterior en el examen ocular, fenotipo facial característico y vértebras en alas de mariposa. Es ocasionado por mutaciones en el JAGGED1 (más del 90%) y en el gen NOTCH2. El diagnóstico diferencial incluye: infecciones, enfermedades genético-metabólicas, atresia biliar, causas idiopáticas. La colestasis, el prurito intenso y los xantomas tienen indicación de coleréticos (ácido ursodesoxicólico) y otras medicaciones (colesteramina, rifampicina, naltrexona). En ciertos casos, la derivación biliar parcial externa ha resultado eficaz. El trasplante hepático está indicado en niños con cirrosis e insuficiencia hepática.


Alagille syndrome (AS) is a multisystemic disease autosomal dominant, with variable expression. The major clinical manifestations are: chronic cholestasis, congenital heart disease, posterior embryotoxon in the eye, characteristic facial phenotype, and butterfy vertebrae. AS is caused by mutations in JAGGED1 (more than 90%) and in NOTCH2. Differential diagnosis include: infections, genetic-metabolic diseases, biliary atresia, idiopathic cholestasis. Cholestasis, pruritus and xanthomas have been successfully treated with choleretic agents (ursodeoxycholic acid) and other medications (cholestyramine, rifampin, naltrexone). In certain cases, partial external biliary diversion has also proved successful. Liver transplantation is indicated in children with cirrhosis and liver failure.


Asunto(s)
Niño , Humanos , Síndrome de Alagille , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/terapia
16.
Rev. GASTROHNUP ; 14(2): 49-54, ene.15, 2012. ilus
Artículo en Español | LILACS | ID: lil-648027

RESUMEN

Introducción: El Síndrome de Alagille corresponde a una alteración autosómica dominante con expresión variable. Se caracteriza por colestasis crónica con escasez de los conductos biliares interlobulares asociada a alteraciones cardiovasculares, oftálmicas, sistema esquelético, riñones y facies característica. Su distribución es mundial con frecuencia de 1 por cada 100000 nacidos vivos. Objetivo: Describir las características clínicas, la evolución y la sobrevida de catorce pacientes, con diagnóstico de Síndrome de Alagille atendidos en un período de 16 años en Medellín, Colombia. Materiales y métodos: Es un trabajo observacional descriptivo de reporte de casos de los hallazgos morfológicos y la evolución de los pacientes con diagnóstico de Síndrome de Alagille. Resultados: Grupo compuesto por ocho niños y seis niñas, con edades entre los dos meses y los diez años al momento de diagnóstico. El síndrome completo se presentó en 28%. Los hallazgos más frecuentes, estenosis valvular de la arteria pulmonar y la alteración vertebral se presentaron en el 79%. Tres pacientes 21%, fallecieron, uno de ellos después de recibir trasplante hepático. De los once sobrevivientes dos niñas fueron sometidas a trasplante y se encuentran en buenas condiciones. Los nueve restantes padecen hepatopatía colestásica crónica y reciben tratamiento médico. Conclusión: El Síndrome de Alagille se debe tener en cuenta en el diagnóstico de colestasis crónica infantil. Para establecer la distribución y frecuencia de esta enfermedad en nuestro país es necesario desarrollar investigaciones que idealmente incluyan el estudio de la mutación genética en los pacientes y su familia cercana.


Introduction: The Alagille Syndrome is an autosomic dominant disorder with variable expression. Chronic cholestasis, characteristic facial appearance and abnormalities heart, skeleton, eye, kydnes with hypoplasia of the biliary ducts. Initial description in France, with mundial distribution her frecuence is 1/100000. Objective: To describe the clinical characteristic and evolutions of fourteen patients with diagnosis Alagille Syndrome in Medellín Colombia. Materials and methods: Descriptive retrospective study with variables obtained from clinical records of patients with diagnosis Alagille Syndrome. Results: Eight boys and six girls. The age at diagnosis varied two months at nine years. Complete syndrome was present in 28%. The most frecuent alterations were valvular stenosis pulmonary artery and failure of anterior vertebral arch fusion (butterfly vertebrae) 79%. The clinical evolution was variable, death occurred in three patients 21%, one girl post liver transplantation. Nine children had chronic hepatopathy controlled with medical treatment and two girls had liver transplantation with satisfactory evolution. Conclusions: In Colombia, the poblational incidence is not defined it is necessary to know the distribution of syndrome at future study.


Asunto(s)
Humanos , Masculino , Femenino , Niño , Colestasis/clasificación , Colestasis/complicaciones , Colestasis/diagnóstico , Colestasis/epidemiología , Colestasis/fisiopatología , Colestasis/genética , Colestasis/metabolismo , Colestasis/prevención & control , Colestasis/psicología , Colestasis/rehabilitación , Síndrome de Alagille/clasificación , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/epidemiología , Síndrome de Alagille/genética , Síndrome de Alagille/historia , Síndrome de Alagille/patología , Síndrome de Alagille/prevención & control
17.
Arch. pediatr. Urug ; 81(3): 158-162, 2010.
Artículo en Español | LILACS | ID: lil-588049

RESUMEN

El síndrome de Alagille es un trastorno autosómico dominante, con expresividad variable, cuya prevalencia es de 1 en 100.000 nacidos vivos. Se caracteriza por manifestaciones hepáticas, anomalías vertebrales y oculares, cardiopatía congénita y dismorfias faciales. Se ha identificado el defecto genético causante en el gen JAG 1, localizado en el cromosoma 20, del cual se describen diferentes mutaciones.El pronóstico de este síndrome es variable y depende fundamentalmente de la entidad de la afectación hepática y los defectos cardiovasculares.Se presenta un paciente de 10 años en el que durante una internación por una patología infecciosa adquirida, se realiza diagnóstico de síndrome de Alagille. Este paciente presenta cuatro de los cinco criterios mayores diagnósticos de la enfermedad: cardiopatía congénita, anomalías vertebrales, embriotoxon posterior y fascies característica. Además antecedentes familiares de cardiopatía congénita y dismorfias faciales, con una genealogía que recuerda el tipo de herencia autosómica dominante.


Alagille Syndrome is an autosomal dominant disorder of variable expression, whose prevalence is 1 in 100 000 births, characterized by cholestasis, vertebral and eye abnormalities, congenital heart disease and characteristic facies. It is caused by mutations in the Jagged 1 gene. Several mutations have been described in this gene, located in chromosome 20. The prognosis of this syndrome is variable and depends on the severity of hepatic or cardiac involvement.We present a 10 year old patient in which Alagille syndrome is diagnosed during a hospital stay for an infectious pathology. This patient has 4 of the 5 major features: characteristic facies, posterior embriotoxon, vertebral defects, congenital heart disease. Presents family history of congenital heart disease and facial dysmorphias with a genealogy that resembles an autosomal dominant disorder.


Asunto(s)
Humanos , Masculino , Niño , Síndrome de Alagille/complicaciones , Síndrome de Alagille/diagnóstico , Anomalías Congénitas
18.
Arch. argent. dermatol ; 50(1): 21-4, ene.-feb. 2000. ilus
Artículo en Español | LILACS | ID: lil-258608

RESUMEN

Se presenta un caso de síndrome de Alagille o de escasez de conductos biliares interlobulares; se realiza la descripción de la clínica e histología de nuestro paciente, así como una revisión de esta patología, destacando el interés del tema debido a la escasa frecuencia de observación


Asunto(s)
Humanos , Masculino , Niño , Síndrome de Alagille/diagnóstico , Colestasis/etiología , Colestasis Intrahepática/etiología , Estenosis de la Válvula Pulmonar/etiología , Pronóstico , Síndrome de Alagille/patología , Síndrome de Alagille/tratamiento farmacológico , Disrafia Espinal/etiología , Xantomatosis/etiología
19.
Bol. Hosp. Niños J. M. de los Ríos ; 33(3): 31-5, sept.-dic. 1997. ilus
Artículo en Español | LILACS | ID: lil-212622

RESUMEN

Se reportan las características clínicas, bioquímicas y anatomopatológicas de dos hermanos de una misma familia, los cuales presentaron ictericia y otros hallazgos sugestivos del síndrome. Sus estudios demostraron la presencia de hipoplasia de vías biliares intrahepáticas asociadas a anormalidades faciales, vertebrales, pero sin evidencia de otros criterios mayores del síndrome en el área cardíaca y ocular. Estos pacientes podrían englobarse dentro de los síndromes incompletos de Alagille. Es el primer estudio reportado en nuestro país con afectación de miembros de una misma familia


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Colestasis/patología , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/terapia
20.
Dermatol. argent ; 3(4): 309-14, oct.-dic. 1997. ilus
Artículo en Español | LILACS | ID: lil-215571

RESUMEN

Se presentan seis pacientes, tres varones y tres mujeres, con síndrome de Alagille o de escasez de conductos biliares interlobulares, que consultaron por colestasis neonatal, prurito y xantomas. El protocolo de estudio incluyó la historia personal y familiar, examen físico, cardiológico, oftalmológico, dermatológico y radiológico. Son los únicos casos de la bibliografía dermatológica nacional consultada


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Síndrome de Alagille/diagnóstico , Manifestaciones Cutáneas , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/genética , Conductos Biliares/anomalías , Colestasis/etiología , Hipercolesterolemia/complicaciones , Hipercolesterolemia/etiología , Prurito/etiología , Síndrome de Alagille/tratamiento farmacológico , Síndrome de Alagille/terapia , Xantomatosis/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...